Ascendis Pharma A/S (ASND) shares ended the last trading session 17.1% higher at $139.57. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 14.1% loss over the past four weeks.This surge in share price came after ASND reported topline results from the pivotal ApproaCH study which evaluated its investigational once-weekly administered TransCon CNP in children aged two to 11 years with achondroplasia, the most common f ...

Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.TransCon CNP (navepegritide), an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to provide sustained release and continuous exposure of active CNP.CNP regulates blood flow, blood pressure, and the reactivity of platelets and leukocytes.Also Read: Ascendis Pharma Faces ...

–   U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults COPENHAGEN, Denmark, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United States Food & Drug Administration (FDA) has granted Orphan Drug exclusivity to YORVIPATH® (palopegteriparatide, developed as TransCon PTH), providing seven years of market exclusivity for YORVIPATH in the United States for t ...

magical_light/iStock via Getty Images Ascendis Pharma (ASND) shocked investors with a big Q2 revenue miss, driven by a large net price cut on Skytrofa that management says was necessary to ensure broader access to the drug. The company did not share the exact price cut, but we can calculate from Q2 demand and adjusted net sales numbers that it is approximately 35%. I am not sure how much of the price cut Ascendis can make up with increased patient numbers, but I am sure that the loss of peak sales on Sk ...

Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.Cantor Fitzgerald writes that the Skytrofa update probably overshadowed another key update from the call: the U.S. pricing for Yorvipath, which came out at $285,000/patient/year, much higher than our expectation of $160-190K.The analyst notes that due to the lower Skytrofa guidance, the company’s cash flow breakeven t ...

A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.An earnings miss and sharply reduced guidance for its ONE commercialized product doomed Ascendis Pharma (ASND -11.27%) to a bad Wednesday on the stock market. The biotech's shares fell by more than 11% in price after it divulged its latest set of quarterly results. By comparison, the bellwether S&P 500 index suffered a relatively modest drop of 0.2%.Declines and misses in the second quarterAscendis, a biot ...

Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.Results in the quarter were primarily impacted by a negative adjustment to prior periods' estimates and assumptions for sales deductions of 27.1 million euros, where 19.5 million euros and 7.6 million euros were attributable to the three months ended March 31, 2024, and periods before January 1, 2024, respectively.Als ...

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Conference Call September 3, 2024 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Moller Mikkelsen - President & Chief Executive Officer Scott Smith - Executive Vice President & Chief Financial Officer Camilla Harder Hartvig - Head of Global Commercial Operation Joe Kelly - US General Manager Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Derek Archila - Wells Fargo Li Watsek - Cantor Gavin Clar ...

COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. “We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch YO ...

YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adultsTransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeksSKYTROFA Q2 revenue of €26 million – 134% year-over-year volume growth offset by negative adjustment of €27 million, resetting market access for continued growthRevising full year 2024 SKYTROFA revenue outlook to €220 - €240 millionConference call today at 4:30 pm ET COPENHAGEN, Denmark, Sept ...